Stock Analiz

Neurocrine Biosciences Inc. (NBIX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Neurocrine Biosciences’s revenue went from $15M in fiscal 2016 to $2.9B in fiscal 2025, growth of about 79.2% a year.

Net income in fiscal 2025 was $479M, a net margin of 16.7%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $3.7B and net income $702M.

Free cash flow was $749M in fiscal 2025 and positive in 8 of the 10 years shown.

The diluted share count rose 18% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $15M162017: $162M172018: $451M182019: $788M192020: $1.0B202021: $1.1B212022: $1.5B222023: $1.9B232024: $2.4B242025: $2.9B25$2.9B
Net income
2016: -$141M162017: -$143M172018: $21M182019: $37M192020: $407M202021: $90M212022: $154M222023: $250M232024: $341M242025: $479M25$479M
Free cash flow
2016: -$110M162017: -$101M172018: $77M182019: $132M192020: $218M202021: $233M212022: $323M222023: $362M232024: $557M242025: $749M25$749M
EPS (diluted)
2016: $-1.63162017: $-1.62172018: $0.22182019: $0.39192020: $4.16202021: $0.92212022: $1.56222023: $2.47232024: $3.29242025: $4.6725$4.67

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3.7B$2.9B$2.4B$1.9B$1.5B$1.1B$1.0B$788M$451M$162M$15M
Gross profit—$2.8B$2.3B$1.8B$1.5B$1.1B$1.0B—$446M$160M$15M
Operating income$887M$619M$570M$251M$249M$102M$163M$72M$37M-$131M-$147M
Net income$702M$479M$341M$250M$154M$90M$407M$37M$21M-$143M-$141M
EPS (diluted)$6.74$4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63
R&D$1.2B$1.0B$731M$565M$464M$328M$275M—$161M$122M$94M
Revenue growth—+21.4%+24.8%+26.8%+31.3%+8.4%+32.7%+74.7%+179.2%+977.5%−24.1%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$1.1B$783M$595M$390M$339M$256M$228M$147M$101M-$94M-$106M
Capital spending-$26M-$34M-$38M-$28M-$16M-$23M-$11M-$15M-$25M-$7M-$4M
Free cash flow$1.0B$749M$557M$362M$323M$233M$218M$132M$77M-$101M-$110M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$158M$168M$300M$0$0——————
Stock-based pay$235M$218M$196M$194M$173M$134M$100M$75M$58M$43M$28M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$1.5B$1.1B$1.0B$989M$711M$801M$670M$651M$516M$83M
Debt—$471M$496M$290M$111M$457M$423M$95M$388M$370M$0
Equity—$3.3B$2.6B$2.2B$1.7B$1.4B$1.1B$637M$481M$372M$315M
Total assets—$4.6B$3.7B$3.3B$2.4B$2.1B$1.7B$1.3B$993M$818M$365M
Shares (diluted)105M102M104M101M99M98M98M96M95M88M87M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—98.2%98.6%97.9%98.4%98.7%99.0%—98.9%99.2%100.0%
Operating margin24.0%21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%
Net margin19.0%16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%
FCF margin28.1%26.2%23.7%19.2%21.7%20.6%20.8%16.8%17.0%-62.7%-735.3%
ROIC—11.3%13.0%7.5%9.9%5.0%8.3%7.9%4.1%-17.7%-46.8%
ROE—14.7%13.2%11.2%9.0%6.5%36.2%5.8%4.4%-38.3%-44.8%

Frequently asked questions

What is Neurocrine Biosciences’s annual revenue?

$2.9B in fiscal 2025 and $3.7B over the twelve months to September 30, 2026.

How much profit does Neurocrine Biosciences make?

Net income was $479M in fiscal 2025 (net margin 16.7%).

Is Neurocrine Biosciences’s revenue growing?

Yes: revenue rose 21.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.